TOP > 外国特許検索 > OPHTHALMIC DRUG SUSTAINED RELEASE DEVICE

OPHTHALMIC DRUG SUSTAINED RELEASE DEVICE NEW

外国特許コード F180009471
整理番号 S2016-0590-C0
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP015783
国際公開番号 WO 2017191759
国際出願日 平成29年4月19日(2017.4.19)
国際公開日 平成29年11月9日(2017.11.9)
優先権データ
  • 特願2016-093496 (2016.5.6) JP
発明の名称 (英語) OPHTHALMIC DRUG SUSTAINED RELEASE DEVICE NEW
発明の概要(英語) The present invention addresses the problem of providing a drug sustained release system useful for treatment of eye diseases. Provided is an ophthalmic drug sustained release device comprising, in a hollow container having at least one opening, a drug sealing portion and an intraocular retention gas sealing portion that is provided adjacent to the drug sealing portion, wherein the drug sealing portion is isolated from the opening by the intraocular retention gas sealing portion being interposed between the drug sealing portion and the opening.
特許請求の範囲(英語) [claim1]
1. At least one opening of the hollow container, the drug in the enclosure portion and adjacent to the sealed portion is provided on the eye dwell gas, the enclosed portion of the drug, the intraocular residing gas encapsulation portion is interposed at the opening by being isolated from, the slow-release drug eye.
[claim2]
2. Wherein said drug in that the encapsulation and the gas encapsulation portion residing within the eye composed of a plurality of units, in that the encapsulation the drug from the aperture such that the distance to be different between the units, each of the units in the eye of the gas encapsulation portion residing directly or via other unit communicates with the opening, the slow-release according to claim 1 ophethalmologic drugs.
[claim3]
3. A plurality of said unit partitions, the partition wall is provided with a plurality of portions, the slow-release according to claim 2 ophethalmologic drugs.
[claim4]
4. A plurality of said unit, along a direction away from the opening portion is provided in series, the slow-release according to claim 2 ophethalmologic drugs.
[claim5]
5. Wherein a container is tubular and is, along its longitudinal axis direction, a plurality of said units are arranged in series, the slow-release according to claim 2 ophethalmologic drugs.
[claim6]
6. Wherein the volume of the gas encapsulation portion residing within the eye are different between the units, the slow-release according to claim 2 ophethalmologic drugs.
[claim7]
7. A hollow container, the drug enclosure portion and the adjacent blocks thereto from the gas encapsulation portion residing in the eye of a plurality of units, a plurality of said units may be partitioned by the partition wall and, within each of the units stored in the eye of the enclosure portion on the outer wall of the gas, an opening is formed after implantation region is provided, the slow-release drug Ophthalmology.
[claim8]
8. Wherein the opening YAG laser, a dye laser or a diode formed by the laser beam, the slow-release according to claim 7 ophethalmologic drugs.
[claim9]
9. When the inside of the container, the plurality of drug enclosure portion and a plurality of eye in a mixed gas encapsulation portion residing in a porous state, the slow-release according to claim 1 ophethalmologic drugs.
[claim10]
10. The drug solution is injected into the container wherein the freeze drying the porous state are formed, the slow-release according to claim 9 ophethalmologic drugs.
[claim11]
11. Wherein the gas residing within the eye, sulfur hexafluoride, octagonal ethylpropane fluoride, and air is selected from the group consisting of one or more of the gases, of any one of claims 1-10 ophethalmologic of the slow-release of the drug.
[claim12]
12. Said container, said gas residing within a low permeability of the eye, from a biocompatible material having a high, according to any one of claims 1-11 of the slow-release drug.
[claim13]
13. As the material, an acrylic resin, a glass, Ti, Ti alloy or a Ni alloy is, according to claim 12 ophethalmologic drug release device.
[claim14]
14. Wherein said drug in that the encapsulation is enclosed in a water-soluble drug, according to any one of claims 1-13 ophethalmologic of the slow-release of the drug.
[claim15]
15. Wherein the medicament is a liquid or solid form drug is encapsulated in the encapsulation, claims 1-8, any one of claims 11-14 wherein the slow-release ophthalmic drug.
[claim16]
16. (A) less than or equal to - (d) the implantation method according to any one of the living being implanted in, any one of claims 1-15 drug ophethalmologic of the slow-release, intracisternal PIOL (a) inserting fixed to the groove-like or hair, and implantation into the eye (b), ciliary body fixed to the flat portion, is inserted into the eye (c), eye (d) placed outside.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • YASUKAWA TSUTOMU
国際特許分類(IPC)
指定国 (WO2017191759)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close